26: 888-896. Background. Five randomized trials, a follow-up study, and six case-control investigations of BCG vaccine's effectiveness (VE) for preventing leprosy have been conducted internationally, with widely varying estimates of VE. Because of the difficulty of generalizing from disparate results, local estimates of VE are needed for health planning purposes and are currently particularly relevant, given the World Health Organization's (WHO) goal to eliminate leprosy by the year 2000. Methods. We conducted a case-control study in Yangon, Myanmar. Residents of Yangon between the ages of 6 years and 24 years who were listed in the National Leprosy Registry as being on active treatment for leprosy between December 1992 and April 1993 were eligible to participate in the study as cases. Control subjects were matched to the cases on age, sex, and neighbourhood. Results. One or more doses of BCG were associated with a VE of 66%. The results show a significant trend of increasing VE with increasing number of BCG doses (one dose, VE = 55%; two doses, VE = 68%; three doses, VE = 87%). One dose of BCG vaccine appeared to provide protection substantially higher than that found in an earlier vaccine trial in Myanmar, but consistent with results from case-control studies in other countries. Conclusions. These data suggest that BCG reduces the risk of leprosy in Myanmar, and that BCG vaccination of infants, along with early case-finding and treatment, should be considered an important part of the leprosy intervention strategy.
Projecting continued progress with multidrug therapy (MDT) coverage, in May 1991, the Forty-Fourth World Health Assembly adopted a resolution on the elimination of leprosy as a public health problem by the year 2000, with elimination defined as attaining a prevalence of less than one per 10 000 people. Prospects for achieving such a goal with MDT alone will depend on early and near complete case-finding, and high compliance with therapy, all of which may prove difficult in the areas with highest leprosy prevalence, such as Myanmar, which ranks fifth in the world in registered leprosy prevalence 1 and where 56% of registered cases are on MDT therapy. 2 Results from five randomized trials, a follow-up study and six case-control studies have shown that BCG vaccine prevents leprosy, but the level of effectiveness varies, for reasons not readily explained. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Because a decade of research has failed to find a new vaccine of proven efficacy against leprosy, the public health value of BCG vaccination against leprosy remains a relevant issue. Local estimates of vaccine effectiveness (VE) for hyperendemic regions like Myanmar may prove useful as an aid to choosing the most cost-effective strategy for controlling leprosy, especially when this choice is made more challenging by lack of resources.
We conducted a case-control study to investigate the effectiveness of BCG vaccine for preventing leprosy in Myanmar. Although estimates of VE are available from a randomized trial conducted 30 years ago in Myanmar (VE = 20%, 95% confidence interval : 7-31), this case-control study provides an evaluation of the BCG vaccination programme in Myanmar, as well as an estimate of VE against the more infectious multibacillary form of leprosy, an issue which could not be addressed by the earlier trial.
MATERIALS AND METHODS
The study was conducted in Yangon, the capital of Myanmar. A list of eligible cases residing in Yangon was compiled from the records of the National Leprosy Registry. Cases were eligible to participate in the study if they were under active treatment (but not for relapse) between December 1992 and the end of April 1993, were not younger than 6 years or older than 24 years of age in 1993, and had been diagnosed on the basis of a slit skin smear and clinical examination by a leprologist. Diagnoses were reviewed by a dermatopathologist with 20 years of clinical experience with leprosy.
The eligible age range was chosen to cover the ages at which leprosy incidence peaks, and to exclude those vaccinated conditional on tuberculin status, a practice abolished in 1968. Starting in 1969, BCG vaccine was administered without regard to tuberculosis or leprosy exposure. In 1978, with implementation of the Expanded Program on Immunization, the BCG vaccination schedule changed from one to three doses. During the period 1969-1993, the type of BCG vaccine varied depending on the donor agency.
For each case, we selected a control subject without leprosy, matched to the leprosy patient on age (within 2 years) and gender, and from the patient's neighbourhood. To select the matched controls, we started the search in the first house to the right of the leprosy patient's house, and moved to the first house to the left, and then to the second house to the right, and so on until an appropriate match to the case was found. The search was aided by consultation of the register which each household is required to keep, listing household members by date of birth.
Cases and controls (or a parent/guardian) were interviewed to determine the history of exposure to leprosy and BCG vaccination, and their socioeconomic status. The interviews were conducted by a paramedic leprosy inspector. Except for a few of the youngest study subjects, recorded vaccination histories were not available, and so we examined all subjects for the presence of BCG scars. The examinations were conducted by a paramedic from the National Tuberculosis Control Programme's BCG scar survey team. In Myanmar, the practice has been to inject BCG vaccine intradermally in the left deltoid region, unless the subject has scabies or another skin condition there, in which case it is injected in the right deltoid region. Therefore, both arms were checked for scars. A more extensive physical examination of the control subjects was done to rule out leprosy. Three potential control subjects with suspicious lesions, anaesthesia, or nerve thickening were excluded from participation in the study.
Because diagnosis of leprosy can be difficult, an algorithm was developed to assign a case-certainty score to each case using the method of Ponnighaus et al. 15 modified to reflect the rare use of punch biopsies in Myanmar (see Appendix).
Conditional logistic regression models were used to estimate BCG vaccine effectiveness according to number of doses of BCG vaccine, and age at vaccination, and to control for potential confounding by socioeconomic status as measured by housing type, education level of the most educated member of the household, or per capita monthly household expenses. The measure of effect from all models was the prevalence odds ratio, an estimator of the incidence density ratio, which approximates the cumulative incidence ratio under the rare disease assumption. 16 VE was defined as one minus the odds ratio, multiplied by 100. A score test was used to evaluate the trend in VE according to number of vaccine doses received. Separate analyses were also conducted for different subtypes of leprosy, with clinical definitions according to the Ridley-Jopling and WHO multibacillary/paucibacillary classification systems. 17, 18 EGRET software was used for all analyses.
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RESULTS
Of 351 registered leprosy patients who were identified initially as being eligible for the study, 12 did not meet the inclusion criteria, 33 had moved away, 38 had listed a fictitious address, and eight were not available to be interviewed. Among the remaining 260, a matching control subject could not be found for 11, and four were not examined for BCG scars. Analysis was restricted to the remaining 245 case-control pairs.
Participants were similar to non-participants with respect to sex (female, 37% versus 33%) and age (older than 14 years of age, 69% versus 68%), and type of leprosy (paucibacillary, 50% versus 50%). Of the participants with leprosy, 1 (0.4%) was diagnosed at age 5 years; 38 (16%) were 6-10 years old, 82 (33%) were 11-15 years old, 83 (34%) were 16-20 years old, and the remaining 41 (17%) were 21-24 years old at diagnosis. When classified by clinical characteristics according to the Ridley-Jopling system, 17 patients with leprosy included in the study were evenly distributed by type, with the exception of those falling into the mid-borderline (BB) classification, who represented only 4% of cases. Fifty per cent of the cases were multibacillary (Table 1) . Among the multibacillary cases, all of the diagnoses were classified as being 'certain' by the case-certainty algorithm. Of the paucibacillary cases, 90% were classified as 'certain', 7% as 'extremely likely', and 2% as 'most likely'.
Sixty-eight (27%) of the leprosy patients and 28 (11%) of the controls were interviewed about socioeconomic circumstances and history of contact with leprosy patients; for the remaining 177 (72%) of the leprosy patients and 217 (89%) of the controls, a parent/guardian was the interview respondent. Cases were more likely to have lived with another leprosy patient in the same household, and cases tended to have lower socioeconomic status than controls from the same neighbourhood, as measured by housing type, education level of the most educated member of the household, and per capita monthly household expenses ( Table 2) . Compared with those living in brick homes (high income housing), those living in huts or semi-huts had higher odds of leprosy. Those living in wooden homes (middle to high income housing) had similar odds of leprosy as brick home dwellers. An inverse association between education level of the most educated member of the household and odds of having leprosy was observed, but the test for trend was non-significant (P = 0.136). Similarly, an inverse association was found between per capita monthly household expenses (a measure of disposable income), categorized by quartiles, and odds of having leprosy, but the test for trend was nonsignificant (P = 0.075). No association was observed between odds of having leprosy and household size or time in residence at present location (not shown in Table 2 ).
Among control subjects, there was a positive association between the proportion BCG vaccinated and the education level of the most educated member of the household. Compared with control subjects coming from households in which the highest educated individual had a grade school education (grades 1-6), the odds of having been BCG vaccinated were five times higher for controls from a household where someone was college-educated (95% CI : 1.9-13.9), four times higher for controls from a household where high school is the highest education level (95% CI : 2.6-6.1), and 1.8 times higher for controls from a household where middle school (grades 7-8) is the highest education level (95% CI : 0.60-3.0).
Estimates of VE from conditional logistic regression analyses are presented in Table 3 . The VE associated with one or more BCG scars was 66% (95% CI : 44-80). There was a trend of increasing vaccine effectiveness with increasing numbers of doses of vaccine, which was significant at P Ͻ 0.001 (even when the zero dose group was excluded). One, two, or three BCG scars were associated with VE estimates of 55%, 68%, and 87%, respectively. Adjustment for differences in socioeconomic status between cases and controls changed the VE estimates very little (Table 4) . Many more leprosy patients than controls had had a household member with leprosy (19% of cases, 1% of controls, Table 2 ). VE calculated for case-control pairs in which the case had household contact was 55%, compared with 66% for pairs in which the case had no household contact, but this difference was not statistically significant. Small numbers prohibited examination of VE by household contact status for one, two, and three doses of BCG separately.
For leprosy subtypes categorized based on clinical presentation according to the Ridley-Jopling classification system, 17 BCG vaccine was more effective against the borderline tuberculoid type (89%) and tuberculoid type (77%) than against the two categories of lepromatous types (BB/BL/LL, 40%; LL, 46%) ( Table 5) . VE was greater for paucibacillary leprosy (74%) than for multibacillary leprosy (57%). These differences were not statistically significant.
Among case-control pairs in which both members of the pair were vaccinated, we compared the odds of having been vaccinated at the age recommended in the vaccine administration schedule or at an age later than the recommended age. Odds ratios were calculated by dose, with control of the matching variables through conditional logistic regression, and the results are shown in Table 6 . For the second and third doses, age at vaccination was not associated with having leprosy. However, for the first dose, the odds of having leprosy among those vaccinated for the first time after the age of one year is approximately 1.7 times the odds of having leprosy in those vaccinated at or before one year of age.
DISCUSSION
The current schedule for administration of BCG vaccine in Myanmar is a single dose at 6 weeks of age. Our results support adherence to this schedule of early first vaccination with BCG, and suggest that such a schedule may prevent up to 40% more cases than one in which first vaccination occurs after the age of one year.
Participants in this study were vaccinated from 1969 to 1993, when donors of BCG vaccine to Myanmar varied. The BCG vaccines administered during this period were unlikely to have been microbiologically identical. Because estimating VE for different types of BCG vaccine was not possible in this study, interpretation of the results must take into account that each VE estimate represents a composite for the group of BCG vaccines used from 1969 to 1993.
The VE estimate from this study associated with one or more doses of BCG was 66%, and the 95% CI suggests that the current number of leprosy cases in Yangon in the age range 6-24 years would be larger by a factor of 1.75-5 if BCG vaccine had not been administered. Compared with the overall VE of 66% against leprosy, an overall VE of 38% against all forms of tuberculosis was reported from a 1986 case-control study in Yangon. 21 That study found 20% effectiveness against primary complex, 52% against tuberculous meningitis, and 80% against disseminated tuberculosis. The higher effectiveness of BCG against leprosy than against some forms of tuberculosis has been found in other areas, for example, in South India, 22 The VE estimated from the earlier randomized trial of BCG against leprosy in Myanmar was much lower than the estimate from this study. In the trial, 23 one dose of BCG vaccine was given, and the estimate of effectiveness was 20% (95% CI : 7-31), compared with an estimate of 55% (95% CI : 21-74) for one dose in our case-control study.
Two possible explanations of the discrepancy between our results and those of the trial are that the distributions of age at first vaccination with BCG were different, being generally younger for the case-control study population (40% versus 10% less than one year old in the trial population), and the prevalence of leprosy was more than five times higher (33 per 1000 at the trial site in 1964, and 6 per 1000 in Yangon currently). The distributions of age at first vaccination are important because those who are older when they receive the first dose of BCG vaccine may have been exposed to and possibly infected with Mycobacterium leprae before vaccination. Our results indicate higher effectiveness when the first dose of BCG was given at or before the age of one year (Table 6 ).
In both the previous trial and our case-control study, the majority of the subjects were not exposed to leprosy at home (88% and 90%, respectively). However, leprosy prevalence at the trial site was higher than in Yangon when the case-control study was conducted, so the probability of exposure to leprosy outside the home was higher for the trial subjects. Because exposure to infection is critical in producing leprosy cases, BCG vaccination, in reducing incidence of infection (and thus reducing the probability of exposure to infection in both vaccinated and unvaccinated individuals), may have had an important indirect effect in reducing overall incidence of leprosy. If the magnitude of this indirect effect depends on intensity of transmission, 24 the indirect effect may have been different in the trial population where intensity of transmission was higher. A difference in indirect effects in the trial and casecontrol study populations may have a role in explaining the divergent results from the two studies. The indirect effects of BCG vaccine on transmission were not estimated for the trial population, and the design of our case-control study did not allow quantification of the indirect effect of BCG vaccine. 24 The six case-control studies of BCG vaccine against leprosy conducted thus far were comparable to our study in Myanmar in terms of ascertainment of cases, matching factors, and methods of assessing BCG exposure. 8, [10] [11] [12] [13] [14] However, the study locations had different policies regarding dosages of BCG vaccine and numbers of BCG doses administered, and the studies had different criteria for inclusion of subjects. These differences must be kept in mind when comparing results across studies. Compared with the VE of 55% (95% CI : 21-74) for one dose of BCG in our study, the VE estimates were higher for one dose in Kenya (81%, 95% CI : 67-90), 14 and Brazil (81%, 95% CI : 63-90), 11 and the VE in South Vietnam was lower (29%, 95% CI : -10 to 55). 12 The VE point estimates for one dose of BCG in S. Malawi (64%, 95% CI : 42-77) 13 and Venezuela (49%, no CI) 8 were of similar magnitude as those obtained in our study in Myanmar.
Our study is the third (the first a case-control study 8 and the second a recent randomized controlled trial 7 ) to report results for more than one dose of BCG. Although the study designs differed, all three studies suggest an added leprosy prevention benefit with repeated vaccination with BCG. In the Karonga Prevention Trial in northern Malawi, 7 a second BCG vaccination gave further protection (about 50%) over a first BCG vaccination. In the case-control study in Venezuela, 8 VE was higher for four or more doses compared with one to three doses, but the difference was not significant. The results from the latter study are somewhat more difficult to interpret, because VE did not show a doseresponse effect as in our study in Myanmar (VE was 49%, 58% and 46% for one, two and three doses, respectively, compared with VE of 55%, 68%, and 87% for one, two, and three doses in Myanmar). One possible explanation of this difference is that eligibility for the study in Venezuela was restricted to contacts of leprosy patients, whereas participants in our study in Myanmar were mostly non-contacts.
It is important to note that in the Karonga Prevention Trial, 7 HIV-infected people had an increased incidence of tuberculosis with repeated BCG vaccination. This finding emphasizes that potential adverse effects of repeated BCG vaccination must be considered when formulating recommendations for local BCG vaccination policy. 25 In our study in Myanmar, a higher VE was observed against paucibacillary disease (74% versus 57% against multibacillary disease), but the difference was not statistically significant. Of the other investigations, those in Kenya, 14 Venezuela, 8 N. Malawi, 9 and S. Malawi, 13 examined the effectiveness of BCG vaccine against multibacillary and paucibacillary leprosy. Studies in S. Malawi 13 and Kenya 14 obtained similar findings of greater VE against paucibacillary disease than against multibacillary disease (73% versus 52% and 83% versus 76%, respectively). But an opposite effect was found in Venezuela (VE was 26% against paucibacillary disease and 97% against multibacillary disease) 8 and N. Malawi (51% versus 84%). 9 Recent work linking the immunological response to M. leprae (which is associated with disease form) and the HLA-DQ genetic locus 26 raises the possibility that different frequencies of HLA types across populations might help to explain differences in overall vaccine effectiveness, and vaccine effectiveness by leprosy type across these populations. Interpreting differences in studies conducted so far, in which there was no identification of differences in susceptibility, is complicated 27 given the complex interplay of vaccine effectiveness with susceptibility, other factors affecting host immune response, and exposure to infection, which may also be associated with type of leprosy if transmission occurs within households where members will tend to be of the same susceptibility type.
We observed higher odds of having leprosy for those vaccinated with BCG for the first time after one year of age compared with those vaccinated at age one year or younger, although the lower limit of the CI was very close to the null value. In interpreting the age at vaccination finding, possible misclassification must be considered, because there was no way to verify self-reported age at vaccination. But the finding is consistent with the notion that BCG is more protective if given at an early age before exposure to leprosy, and with the results of the earlier randomized trial conducted in Myanmar. 23 We acknowlege that misclassification of BCG scar presence and number was possible in this study, because documentation of number of BCG vaccine doses received by participants was unavailable (except for some of the youngest participants). Without documentation, there was no way to verify vaccination status. Fine et al. 28 concluded from a study of BCG scars in Malawi that validity and reliability of BCG scar reading may be lower than previously reported. However, it is important to note that the situation in Myanmar differed from that in Malawi in at least one important respect, namely that the dosage of BCG vaccine given in Myanmar has been 0.1 ml, 29 which is double the dosage given in Malawi to infants younger than 3 months of age. 9 The higher dosage may leave a more definite scar, so sensitivity of scar reading might be expected to be higher in Myanmar. [30] [31] [32] In evaluating the possibility of misclassification of scar status in our case-control study, we considered 'misreading' of scars. Of the 490 subjects in the casecontrol study, four were found to have 'doubtful' scars. Of these, two were members of a discordant pair (and thus contributed to the measure of effect in the matched analysis); one subject had one definite and one 'doubtful' scar, and the second subject had a single 'doubtful' scar. Coding the equivocal scars as definite 'yes' or definite 'no' for these two subjects did not appreciably change the results obtained for overall vaccine effectiveness.
To investigate further the reliability and agreement of the scar reading, we conducted a substudy involving a 10% random sample of the study population. For these subjects, the presence and number of BCG scars was evaluated three times. Six to ten months after the initial reading, the scar assessment was repeated by the initial reader, and an independent assessment was made by an additional reader. The intra-observer comparison showed agreement for all but one subject in the sample, with the chance-corrected agreement (kappa) being 96.7% (100% represents perfect agreement). These results support the reliability of scar reading. However, as a method for identifying vaccinated individuals, scar reading is unlikely to be 100% accurate. In particular, the sensitivity of scar reading might be reduced by the possibility that for some individuals, improper injection technique or mixing of the vaccine could have resulted in poor scarring.
Finally, because it was impossible to blind the scar readers to the leprosy status of study participants, differential misclassification of scar status cannot be ruled out, but there is no reason to believe that controls were examined more carefully for BCG scars than leprosy patients.
CONCLUSION
The results reported indicate that BCG vaccine is having at least some, and possibly a substantial, preventive effect against leprosy. The protection afforded by BCG vaccine was found to be higher when the first dose was given before the age of one year, and the level of protection increased with the number of doses given. These results suggest that in Myanmar, BCG vaccination of infants, together with early case-finding and treatment, should be considered an important part of the leprosy intervention strategy.
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